{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-337962","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2026-08-06T20:05:37+00:00","discovered_at":"2026-08-06T20:07:10.269219+00:00","generated_at":"2026-08-06T20:07:45.846878+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ResMed Q4 revenue up 9% to $1.5B; non-GAAP EPS $2.95 (+16%); dividend raised 10%","bullets":["Q4 revenue $1.464B (+9% YoY); GAAP EPS $2.64 (+2%); non-GAAP EPS $2.95 (+16%).","FY2026 revenue $5.653B (+10%); GAAP EPS $10.43; non-GAAP EPS $11.17 (+17%).","FY2026 free cash flow $1.6B; returned $1.0B to shareholders; FY2027 capital return guided >$1.85B.","Dividend increased 10% to $0.66/quarter; record date Aug 20, payable Sep 24.","Agreement to sell MatrixCare (close Q1 FY2027); completed acquisition of Noctrix Health."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-337962","json":"https://secwatch.observer/filing/0001193125-26-337962.json","markdown":"https://secwatch.observer/filing/0001193125-26-337962.md","text":"https://secwatch.observer/filing/0001193125-26-337962.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312526337962/0001193125-26-337962-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312526337962/d158732d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:07:45.846878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}